AIMT
Aimmune Therapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Market Cap: 2.26 Billion
Primary Exchange: NASDAQ
Website: http://www.aimmune.com
Shares Outstanding: 65.5 Million
Float: 51.8 Million
Dividend: (%)
Beta: 1.0098815883328294
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 1237 trading days
From: 2017-12-22 To: 2020-10-13
Lowest Point:
Aimmune to Present at the JMP Securities Life Sciences Conference
via: Business Wire at 2019-06-12 04:00:00:000
Aimmune Therapeutics, Inc.(Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday… read more...
Aimmune to Present at the JMP Securities Life Sciences Conference
via: Business Wire at 2019-06-12 04:00:00:000
Aimmune Therapeutics, Inc.(Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday… read more...
Aimmune Therapeutics Discusses AR101's Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
via: Business Wire at 2019-06-11 04:00:00:000
Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic … read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|